Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9

Leukemia volume 19, pages 138–140 (2005)Cite this article

TO THE EDITOR

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder arising from a pluripotent haematopoietic stem cell. The cytogenetic hallmark of CML is the Philadelphia-chromosome (Ph), a reciprocal product of translocation between chromosomes 9 and 22, which is detected in over 90% of CML patients. Variant forms of Ph translocation affecting additional chromosomes, are seen in 5–10% of the patients.1

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Mitelman F, Johansson B, Mertens F (eds). Mitelman database of chromosome aberrations in cancer, 2004. http://cgap.nci.nih.gov/Chromosomes/Mitelman.

  2. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–743.

    CAS  PubMed  Google Scholar 

  3. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C et al. Imatinib improves but may not fully reverse the poor prognosis of CML patients with derivative chromosome 9 deletions. Blood 2003; 102: 2205–2212.

    Article  CAS  PubMed  Google Scholar 

  4. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  PubMed  Google Scholar 

  5. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738.

    Article  CAS  PubMed  Google Scholar 

  6. Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588.

    Article  CAS  PubMed  Google Scholar 

  7. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP . Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003; 121: 419–427.

    Article  PubMed  Google Scholar 

  8. Kolomietz E, Marrano P, Yee K, Thai B, Braude I, Kolomietz A et al. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia 2003; 17: 1313–1323.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Drs Sanna Siitonen and Kirsi Autio for assistance with patient samples, Dr Johan Lundin for statistical analysis assistance and Sanna Vesala for dedicated patient record care. This work was supported by grants from the Finnish Medical Research Fund, the Finnish Cancer Society, Signe and Ane Gyllenberg Foundation, Cancer Society of Northern Finland, The Research Fund for Blood Diseases and Helsinki and Oulu University Hospital research funds.

Author information

Authors and Affiliations

  1. Basic Science and Stem Cell Laboratory, Department of Medicine, Division of Hematology, University of Helsinki, Helsinki, Finland

    T Lundán & K Porkka

  2. Departments of Pathology and Medical Genetics, Haartman Institute, University of Helsinki and HUSLAB Helsinki University Central Hospital, Helsinki, Finland

    T Lundán & S Knuutila

  3. Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland

    L Volin, T Ruutu & K Porkka

  4. Department of Clinical Genetics, University of Oulu and Oulu University Hospital, Oulu, Finland

    T Lundán

Authors
  1. T Lundán
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Ruutu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Knuutila
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Porkka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Porkka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundán, T., Volin, L., Ruutu, T. et al. Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9. Leukemia 19, 138–140 (2005). https://doi.org/10.1038/sj.leu.2403570

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403570

Search

Advanced search

Quick links